ARTICLE | Company News
Priority Review for simeprevir from J&J, Medivir
May 14, 2013 12:26 AM UTC
FDA accepted and granted Priority Review to an NDA from the Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) for simeprevir to treat HCV genotype 1 infection in adult patients w...